Rutie Yin

12PUBLICATIONS
47CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer diagnosisPredictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Feb 19, 2026
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial.

Yuanming Shen, Nalan Tu, Beihua Kong

|Dec 17, 2025
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).

Li Wang, Lingling Xie, Qingshui Li

|May 24, 2025
The role of innate immunity triggered by HPV infection in promoting cervical lesions.

Kaiyu Fu, Xin Yang, Mengpei Zhang

|Jun 14, 2024
First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.

Xiaohua Wu, Jihong Liu, Ruifang An

|May 31, 2023
HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients.

Lei Li, Yu Gu, Mengpei Zhang

|Apr 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.

Ning Li, Youzhong Zhang, Jing Wang

Pageof 2

Frequent Collaborators

6 joint publications

Yaping Zhu

3 joint publications

Kemin Li

2 joint publications

Jihong Liu

2 joint publications

Ning Li